Rates of Medically Attended RSV Among US Adults: A Systematic Review and Meta-analysis

John M. McLaughlin(Pfizer (United States)), Ann R. Falsey(Rochester General Hospital), Luis Jódar(Pfizer (United States)), Elizabeth Begier(Pfizer (United States)), Farid Khan(Pfizer (United States)), David L. Swerdlow(Epidemic Intelligence Service)

Open Forum Infectious Diseases

June 17, 2022

10.1093/ofid/ofac300

Cited by 212

Related Papers

Respiratory Syncytial Virus Infection in Elderly and High-Risk Adults

|New England Journal of Medicine|2005|2.2k

Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data

|The Lancet|2021|1.7k

Hospitalized Patients with 2009 H1N1 Influenza in the United States, April–June 2009

|New England Journal of Medicine|2009|1.7k

H1N1 2009 influenza virus infection during pregnancy in the USA

|The Lancet|2009|1.4k

Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study

|The Lancet|2021|1.3k